Barclays
KALV

Barclays’s KalVista Pharmaceuticals KALV Stock Holding History

Barclays’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-50,800
Closed -$574K – 5611
2025
Q2 		$574K Buy
+50,800
New +$621K ﹤0.01% 3687

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Barclays's KALV Position: Q1 2026 in Review

Barclays reduced its KalVista Pharmaceuticals (KALV) stake by 23% in Q1 2026, selling an estimated $2.64M and leaving 537,061 shares worth $10.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1412.

Barclays first reported a position in KALV in Q2 2015 and has held it in 35 quarters since. The position peaked at $11.3M in Q4 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Barclays held 537,061 shares of KalVista Pharmaceuticals worth $10.8M as of Q1 2026.
  • Barclays sold 163,512 KalVista Pharmaceuticals shares in Q1 2026, an estimated $2.64M.
  • KalVista Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1412 holding.
  • Barclays first reported a position in KalVista Pharmaceuticals in Q2 2015 and has held it in 35 quarters since.
  • Barclays's KalVista Pharmaceuticals position peaked at $11.3M in Q4 2025.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.